Solventum reports Q4 2025 sales $2B, organic sales +3.5%; full-year adjusted EPS $6.11, down 8.8% YoY

Solventum Corp

2025-FY EPS reported $8.88 revenue$8,325,000,000

Q4 reported sales $1,998M (-3.7% YoY); organic sales +3.5% driven by MedSurg and Dental.
GAAP diluted EPS $0.36; adjusted diluted EPS $1.57 (+11.3% YoY).
Full-year 2025 adjusted EPS $6.11 (down 8.8% from $6.70); free cash flow -$10M vs $805M in 2024.
Introduced 2026 full-year guidance for organic sales growth, adjusted EPS, and free cash flow.
CEO Bryan Hanson: full-year 2025 results ahead of expectations; solid progress toward long-range plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.